Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
01
04
2020
accepted:
16
06
2020
revised:
06
06
2020
pubmed:
2
7
2020
medline:
22
6
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
Myeloid sarcoma (MS) as a solid extra-medullary (EM) manifestation of acute myeloid leukemia (AML), myeloproliferative or myelodysplastic syndromes is a rare presentation of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The databases of the Departments of Hematology and Oncology of the University Hospitals of Jena and Rostock were screened for patients aged 18 years or older for onset of MS after HSCT for myeloid malignancies between 2002 and 2019. Nineteen patients with MS were identified, the majority of whom had received reduced-intensity conditioning (RIC). The median onset of MS was 425 days after HSCT and the median overall survival since MS was 234 days. Although MS is associated with a poor prognosis, three patients survived more than two years and one more than 11 years after MS onset. These results indicate that RIC protocols may be associated with a higher risk of EM relapse. Since EM relapse occurred in the presence of Graft-versus-host-disease, these observations also demonstrate the limitations of graft-versus-tumor effects after HSCT. In conclusion, occurrence of MS after HSCT is associated with a poor prognosis, as multimodal curative concepts including intensive chemotherapy and another HSCT are often not viable.
Identifiants
pubmed: 32606455
doi: 10.1038/s41409-020-0984-4
pii: 10.1038/s41409-020-0984-4
pmc: PMC7796857
doi:
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-109Références
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51. https://doi.org/10.1182/blood-2009-03-209262 .
doi: 10.1182/blood-2009-03-209262
pubmed: 19357394
Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21:340–50. https://doi.org/10.1038/sj.leu.2404491 .
doi: 10.1038/sj.leu.2404491
pubmed: 17170724
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. https://doi.org/10.1182/blood-2016-03-643544 .
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
pmcid: 27069254
Campidelli C, Agostinelli C, Stitson R, Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132:426–37. https://doi.org/10.1309/AJCP1ZA7HYZKAZHS .
doi: 10.1309/AJCP1ZA7HYZKAZHS
pubmed: 19687319
Wilson CS, Medeiros LJ. Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol. 2015;144:219–39. https://doi.org/10.1309/AJCPO58YWIBUBESX .
doi: 10.1309/AJCPO58YWIBUBESX
pubmed: 26185307
Xie N, Zhou J, Zhang Y, Yu F, Song Y. Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective study. Med (Baltim). 2019;98:e15584. https://doi.org/10.1097/MD.0000000000015584 .
doi: 10.1097/MD.0000000000015584
Cunningham I. Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma. 2006;47:1754–67. https://doi.org/10.1080/10428190600632857 .
doi: 10.1080/10428190600632857
pubmed: 17064985
Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transpl. 2000;26:147–52. https://doi.org/10.1038/sj.bmt.1702488 .
doi: 10.1038/sj.bmt.1702488
Magdy M, Abdel Karim N, Eldessouki I, Gaber O, Rahouma M, Ghareeb M. Myeloid sarcoma. Oncol Res Treat. 2019;42:224–9. https://doi.org/10.1159/000497210 .
doi: 10.1159/000497210
pubmed: 30840960
Solh M, Solomon S, Morris L, Holland K, Bashey A. Extramedullary acute myelogenous leukemia. Blood Rev. 2016;30:333–9. https://doi.org/10.1016/j.blre.2016.04.001 .
doi: 10.1016/j.blre.2016.04.001
pubmed: 27094614
Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017;17:263–7. https://doi.org/10.1016/j.clml.2017.02.027 .
doi: 10.1016/j.clml.2017.02.027
pubmed: 28342811
Stolzel F, Luer T, Lock S, Parmentier S, Kuithan F, Kramer M. et al. The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial. Haematologica. 2019. https://doi.org/10.3324/haematol.2019.223032 .
Yoshihara S, Ando T, Ogawa H. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transpl. 2012;18:1800–7. https://doi.org/10.1016/j.bbmt.2012.05.010 .
doi: 10.1016/j.bbmt.2012.05.010
Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003;82:336–42. https://doi.org/10.1007/s00277-003-0654-9 .
doi: 10.1007/s00277-003-0654-9
pubmed: 12728337
Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, et al. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone Marrow Transpl. 2012;47:1171–7. https://doi.org/10.1038/bmt.2011.242 .
doi: 10.1038/bmt.2011.242
Hilgendorf I, Winkelmann N, Frietsch JJ, Hunstig F, Schnetzke U, Scholl S, et al. Treosulfan, fludarabine and cytarabine as conditioning before allogeneic hematopoietic stem cell transplantation. Blood. 2018;132:5702–5702. https://doi.org/10.1182/blood-2018-99-118259 .
doi: 10.1182/blood-2018-99-118259
Jethava YS, Sica S, Savani B, Socola F, Jagasia M, Mohty M, et al. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transpl. 2017;52:1504–11. https://doi.org/10.1038/bmt.2017.83 .
doi: 10.1038/bmt.2017.83
Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620–9. https://doi.org/10.1182/blood-2002-05-1340 .
doi: 10.1182/blood-2002-05-1340
pubmed: 12393457
Mohty M, Malard F, Blaise D, Milpied N, Socie G, Huynh A, et al. Sequential regimen of clofarabine, cytarabine and reduced intensity conditioning (RIC) prior to allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) in primary treatment failure. Blood. 2014;124:1228–1228. https://doi.org/10.1182/blood.V124.21.1228.1228 .
doi: 10.1182/blood.V124.21.1228.1228
Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. https://doi.org/10.1182/blood-2016-08-733196 .
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 5291965
Fleischmann T, Hilgendorf I, Franiel T. Das Myelosarkom der Hypophyse – eine Rarität eines isolierten Rezidivs einer akuten myeloischen Leukämie. Rofo. 2018;190:273–4. https://doi.org/10.1055/s-0043-122080 .
doi: 10.1055/s-0043-122080
pubmed: 29156477
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. https://doi.org/10.1097/00007890-197410000-00001 .
doi: 10.1097/00007890-197410000-00001
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56. https://doi.org/10.1016/j.bbmt.2005.09.004 .
doi: 10.1016/j.bbmt.2005.09.004
Hanel M, Friedrichsen K, Hanel A, Herbst R, Morgner A, Neser S, et al. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie. 2001;24:356–60. https://doi.org/10.1159/000055107 .
doi: 10.1159/000055107
pubmed: 11574763
Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012;30:3604–10. https://doi.org/10.1200/JCO.2012.42.2907 .
doi: 10.1200/JCO.2012.42.2907
pubmed: 22965967
Schroeder T, Rautenberg C, Haas R, Germing U, Kobbe G. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018;107:138–50. https://doi.org/10.1007/s12185-017-2364-4 .
doi: 10.1007/s12185-017-2364-4
pubmed: 29143282
Wolleschak D, Schalk E, Krogel C, Schnoeder TM, Luehr H, Jentsch-Ullrich K, et al. Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. J Hematol Oncol. 2013;6:39. https://doi.org/10.1186/1756-8722-6-39 .
doi: 10.1186/1756-8722-6-39
pubmed: 23759001
pmcid: 3686641
Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984–97. https://doi.org/10.1016/S1470-2045(19)30150-0 .
doi: 10.1016/S1470-2045(19)30150-0
pubmed: 31175001
Funke I, Wiesneth M, Platow S, Kubanek B. Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients. Ann Hematol. 2000;79:132–7. https://doi.org/10.1007/s002770050568 .
doi: 10.1007/s002770050568
pubmed: 10803935
Sperr WR, Hauswirth AW, Wimazal F, Knobl P, Geissler K, Valent P. Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr. 2003;115:505–14. https://doi.org/10.1007/BF03041034 .
doi: 10.1007/BF03041034
pubmed: 13677269
Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–24. https://doi.org/10.1002/cncr.22496 .
doi: 10.1002/cncr.22496
pubmed: 17315155
Alakel N, Stolzel F, Mohr B, Kramer M, Oelschlagel U, Rollig C, et al. Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Manag Res. 2017;9:97–102. https://doi.org/10.2147/CMAR.S125259 .
doi: 10.2147/CMAR.S125259
pubmed: 28435324
pmcid: 5386598
Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer. 1999;85:608–15. https://doi.org/10.1002/(Sici)1097-0142(19990201)85:3<608::Aid-Cncr11>3.0.Co;2-5 .
doi: 10.1002/(SICI)1097-0142(19990201)85:3<608::AID-CNCR11>3.0.CO;2-5
Yuda S, Fuji S, Onishi A, Tanaka T, Inamoto Y, Kurosawa S, et al. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1152–7. https://doi.org/10.1016/j.bbmt.2019.01.011 .
doi: 10.1016/j.bbmt.2019.01.011
Clark WB, Strickland SA, Barrett AJ, Savani BN. Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2010;95:860–3. https://doi.org/10.3324/haematol.2010.025890 .
doi: 10.3324/haematol.2010.025890
pubmed: 20513805
pmcid: 2878780
Curley C, Durrant S, Kennedy GA. Is extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation associated with improved survival? Asia Pac J Clin Oncol. 2013;9:285–9. https://doi.org/10.1111/ajco.12058 .
doi: 10.1111/ajco.12058
pubmed: 23418909
Chevallier P, Mohty M, Lioure B, Michel G, Contentin N, Deconinck E, et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol. 2008;26:4940–3. https://doi.org/10.1200/JCO.2007.15.6315 .
doi: 10.1200/JCO.2007.15.6315
pubmed: 18606981
Rautenberg C, Germing U, Haas R, Kobbe G, Schroeder T. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment. Int J Mol Sci. 2019;20:228. https://doi.org/10.3390/ijms20010228 .
doi: 10.3390/ijms20010228
pmcid: 6337734
Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P, et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transpl. 2005;36:683–9. https://doi.org/10.1038/sj.bmt.1705123 .
doi: 10.1038/sj.bmt.1705123
Au WY, Kwong YL, Lie AK, Ma SK, Liang R. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol. 1999;17:45–52. https://doi.org/10.1002/(sici)1099-1069(199906)17:2<45::aid-hon641>3.0.co;2-6 .
doi: 10.1002/(SICI)1099-1069(199906)17:2<45::AID-HON641>3.0.CO;2-6
Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transpl. 2016;51:1431–8. https://doi.org/10.1038/bmt.2016.167 .
doi: 10.1038/bmt.2016.167
Solh M, DeFor TE, Weisdorf DJ, Kaufman DS. Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. Biol Blood Marrow Transpl. 2012;18:106–12. https://doi.org/10.1016/j.bbmt.2011.05.023 .
doi: 10.1016/j.bbmt.2011.05.023
Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, et al. Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front Immunol. 2017;8:496. https://doi.org/10.3389/fimmu.2017.00496 .
doi: 10.3389/fimmu.2017.00496
pubmed: 28638379
pmcid: 5461268
Cassady K, Martin PJ, Zeng D. Regulation of GVHD and GVL activity via PD-L1 interaction with PD-1 and CD80. Front Immunol. 2018;9:3061. https://doi.org/10.3389/fimmu.2018.03061 .
doi: 10.3389/fimmu.2018.03061
pubmed: 30622541
pmcid: 6308317
Simpson DR, Nevill TJ, Shepherd JD, Fung HC, Horsman DE, Nantel SH, et al. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transpl. 1998;22:259–64. https://doi.org/10.1038/sj.bmt.1701319 .
doi: 10.1038/sj.bmt.1701319
Chevallier P, Labopin M, Cornelissen J, Socie G, Rocha V, Mohty M, et al. Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Haematologica. 2011;96:1391–4. https://doi.org/10.3324/haematol.2011.041418 .
doi: 10.3324/haematol.2011.041418
pubmed: 21685467
pmcid: 3166114
Bernasconi P, Borsani O. Immune escape after hematopoietic stem cell transplantation (HSCT): from mechanisms to novel therapies. Cancers (Basel) 2019; 12. https://doi.org/10.3390/cancers12010069 .
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl J Med. 2016;375:143–53. https://doi.org/10.1056/NEJMoa1601202 .
doi: 10.1056/NEJMoa1601202
pubmed: 27410923
pmcid: 5149459
Lazzarotto D, Candoni A, Fili C, Forghieri F, Pagano L, Busca A, et al. Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results a Multicent Surv Leuk Res. 2017;53:74–81. https://doi.org/10.1016/j.leukres.2016.12.003 .
doi: 10.1016/j.leukres.2016.12.003
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9. https://doi.org/10.1182/blood-2005-05-2004 .
doi: 10.1182/blood-2005-05-2004
pubmed: 15994282
pmcid: 15994282
Johansen S, Kollsete Gjelberg H, Ahmed AB, Bruserud O, Reikvam H. Myeloid sarcoma after allogenic stem cell transplantation for acute myeloid leukemia: successful consolidation treatment approaches in two patients. Case Rep. Oncol Med. 2018;2018:7697283. https://doi.org/10.1155/2018/7697283 .
doi: 10.1155/2018/7697283
pubmed: 29682375
pmcid: 5851332
Cho SF, Liu TC, Chang CS. Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation. Ann Hematol. 2013;92:133–5. https://doi.org/10.1007/s00277-012-1540-0 .
doi: 10.1007/s00277-012-1540-0
pubmed: 22878457
Lin HW, Shih SR, Yao M, Huang TS. Relapse of acute myeloid leukemia at the pituitary gland: a case report and review of literature. Endocr Pathol. 2012;23:172–6. https://doi.org/10.1007/s12022-012-9203-1 .
doi: 10.1007/s12022-012-9203-1
pubmed: 22527946
Muller CI, Engelhardt M, Laubenberger J, Kunzmann R, Engelhardt R, Lubbert M. Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7. Eur J Haematol. 2002;69:115–9. https://doi.org/10.1034/j.1600-0609.2002.02763.x .
doi: 10.1034/j.1600-0609.2002.02763.x
pubmed: 12366717
Kurtz JE, Andres E, Veillon F, Maloisel F, Gentine A, Herbrecht R, et al. Hearing loss due to acute leukemia. Am J Med. 2000;109:509–10. https://doi.org/10.1016/S0002-9343(00)00563-5 .
doi: 10.1016/S0002-9343(00)00563-5
pubmed: 11184771
Khan AA, Nazir S, Ahmed A. Relapse of acute myeloid leukemia presenting as acute otitis media. QJM. 2010;103:533–4. https://doi.org/10.1093/qjmed/hcp138 .
doi: 10.1093/qjmed/hcp138
pubmed: 19793871